EIP Pharma Company
%20.jpg)
EIP Pharma is a private company that has licensed-in and is developing neflamapimod. It has conducted animal studies to position the drug as a treatment for diseases of the brain, including Alzheimer's diseases. Neflamapimod had previously completed a full chronic toxicology program and had demonstrated significant clinical and anti-inflammatory activity in a phase 2a 12-week treatment study in rheumatoid arthritis (RA). EIP Pharma was licensed neflamapimod in 2012.
Technology:
NeuroTech
Headquarters:
Cambridge, Massachusetts, United States
Total Funding:
$72.8M
Last Funding Type:
Post-IPO Equity
Founded Date:
2014-01-01
Industry:
Biopharma, Biotechnology, Pharmaceutical
Employee Number:
1-10
Estimated Revenue:
$10M to $50M